Objectives: To evaluate the histologic characteristics of paranasal sinus mucosa of a disease control population and children with chronic rhinosinusitis and cystic fibrosis (CRS/CF) (1) to determine whether goblet cell (GC) hyperplasia and/or submucosal gland (SMG) hyperplasia occur in pediatric CRS/CF and (2) to compare expression and localization of MUC5AC and MUC5B mucins in the sinus mucosa of both cohorts.
C
YSTIC FIBROSIS (CF) IS A multiorgan obstructive exocrinopathy characterized by chronic inflammation, recurrent infections, and abnormal respiratory tract mucus secretions. 1 Many patients with CF develop chronic rhinosinusitis (CRS); these patients (CRS/CF) often exhibit nasal polyposis and chronic mucus hypersecretion/overproduction and obstruction, which alters their sinonasal mucociliary clearance patterns. [2] [3] [4] Mucus hypersecretion/overproduction in respiratory tract diseases is the culmination of several complex processes, including hyperplasia of mucin-secreting goblet cells (GCs) in the conducting epithelium and/or hyperplasia of submucosal glands (SMGs). 5 Goblet cell and/or SMG hyperplasia can be age, disease, and/or tissue specific. For example, both GC and SMG hyperplasia are more prevalent with age in the lower respiratory tract tissues of patients with CF. 6, 7 In contrast, adult and pediatric patients with CRS exhibit SMG hyperplasia 8, 9 but not GC hyperplasia 8, 10 in their sinus mucosa. It is not known whether patients with CRS/CF express the same phenotype in their sinus mucosa as those with just CRS.
Mucins are the major macromolecular components of mucus and account for its rheologic properties. 11, 12 Mucins are characterized by tandem repeats in their protein backbones and are encoded by a spe-cific human MUC gene. MUC5B and MUC5AC, 2 of the 18 mucins identified to date, are the major mucins expressed in the respiratory tract. 5 MUC5AC is usually restricted to GCs in the lower 13 and upper 10 respiratory tracts. MUC5B, typically restricted to SMGs in the lungs of both disease controls and patients with CF, 14 is expressed not only in SMGs but also in GCs in the sinus mucosa of disease control patients and patients with CRS. 9 In addition, MUC5B is reported to be increased in sinus mucosal secretions from adults with CRS 15 and in nasal polyps from adults with CF, 16 suggesting a role for MUC5B in the upper respiratory tract of adults with CRS or CRS/CF.
Patients with CF often develop CRS, 2,3 and the mucus hypersecretion and obstruction associated with CRS/CF may be complicated by alterations in mucin expression or localization. However, to our knowledge, there is no literature describing the expression or distribution of mucins in the sinonasal tissues of children or adults with CRS/CF, highlighting the need for further research. Altered mucin expression in the sinus mucosa of patients with CRS/CF vs those with CRS or disease controls would suggest that this alteration contributes to the mucus hypersecretion/obstruction observed in patients with CRS/CF. The objectives of this study were to evaluate the histologic characteristics of paranasal sinus mucosa of a disease control population and children with CRS/CF and determine whether GC hyperplasia and/or SMG hyperplasia occur with CRS/CF and to compare expression and localization of MUC5AC and MUC5B mucins in the sinus mucosa of both cohorts.
METHODS

PATIENT POPULATION
Tissue samples were obtained from patients with CRS/CF who underwent an endoscopic sinus surgical procedure (ESS) for CRS refractory to medical management. All patients were classified as children (Ͻ21 years) by National Institutes of Health criteria (http://grants.nih.gov/grants/guide/notice-files/not98-024 .html). Cystic fibrosis was confirmed by sweat test and/or genetic evaluation for the CFTR gene (OMIM *602421). Chronic rhinosinusitis was defined as the presence of symptoms for more than 3 months, despite antimicrobial and topical nasal corticosteroid therapies, and included at least 2 of the major signs and symptoms: nasal congestion, rhinorrhea, headache, facial pain/pressure, nasal obstruction, or change in olfaction. 17, 18 All patients in the CRS/CF cohort underwent nasal endoscopy before ESS and received antibiotics and/or topical nasal corticosteroids at the time of the operation. Pulmonologists evaluated the children with CRS/CF before surgery. Patients with ciliary dyskinesias or craniofacial abnormalities were excluded. Computed tomography scans of the sinuses were obtained, evaluated, and scored by means of the Lund-Mackay system 17 in the CRS/CF group; all scans received a minimum score of 8.
Sinus tissues from patients who underwent craniofacial and/or neurosurgical procedures for abnormalities other than sinusitis served as disease controls. Exclusion criteria for the disease controls included a history of sinonasal operations, current sinonasal infection, sinonasal or allergic symptoms within the preceding 3 months, and/or treatment with topical nasal corticosteroids within 1 month or antihistamines within 3 months before the operation. A combination of computed tomography scans and/or magnetic resonance images with sinonasal sections was obtained. There was no radiographic evidence of sinusitis at the time of the operation for children in the disease control group. 10 All patients were entered consecutively into the study after appropriate surgical and research consents (and assents when applicable) were obtained. This study was reviewed and approved by the institutional review board of Children's National Medical Center. There was no disease control group for CF without CRS because the institutional review board cannot give approval for obtaining sinus mucosa from patients with CF without CRS that is recalcitrant to medical management.
SPECIMEN COLLECTION, PROCESSING, AND HISTOCHEMICAL STAINING
By means of standard endoscopic techniques, directed biopsies were taken from the right and left paranasal sinuses at the time of ESS, based on medical necessity. All patients with CRS/CF had sinus tissues collected from either the maxillary or ethmoid sinuses in the vicinity of the osteomeatal complex. Whenever possible, sinus tissues from the disease controls were also collected as close as possible to the osteomeatal complex. Either maxillary and/or anterior ethmoid sinus mucosa was evaluated in 14 of 18 disease controls. In 2 disease controls, sphenoid sinus mucosa was analyzed. Data on the specific sinus entered were not recorded for 2 of the disease controls. Tissues were fixed in 10% neutral buffered formalin (pH, 6.8-7.2; Richard-Allan Scientific, Kalamazoo, Michigan) for paraffin embedding and sectioning. Tissue sections (5 µm) were cut in the Division of Pathology at Children's National Medical Center. Each slide was stained with hematoxylin and eosin to evaluate tissue quality.
IMMUNOCHEMISTRY
Protocols were adapted from previous studies performed on patients with CRS and children used as disease controls at Children's National Medical Center. 9, 10 Briefly, paraffin sections were de-paraffinized and endogenous peroxidase activity was blocked using hydrogen peroxide in methyl alcohol (30 minutes). Sections were incubated with a MUC5AC mouse monoclonal antibody (1:300; Lab Vision Corporation, Fremont, California) and a MUC5B rabbit polyclonal antibody (1:300, sc-20119; Santa Cruz Biotechnology, Inc, Santa Cruz, California) overnight at 4°C. After phosphate-buffered saline washes, sections were incubated with biotinylated horse antimouse or horse antirabbit antibody (1:250; Vector Laboratories, Burlingame, California) for 1 hour. Secondary antibody was detected with a stain (Vectastain ABC Elite Kit; Vector Laboratories) and 3Ј3Јdiamino-benzidine substrate (Sigma-Aldrich Co, St Louis, Missouri). Slides were counterstained with hematoxylin (Sigma-Aldrich Co) and mounted. In double-staining experiments with Alcian blue/periodic acid-Schiff (AB/PAS), before counterstaining with hematoxylin, slides were stained with Alcian blue (30 minutes), rinsed, and treated with periodic acid (10 minutes) and Schiff reagent (5 minutes). Slides were then counterstained with hematoxylin and mounted. Omission of primary antibody was a negative control. Human stomach tissue was a positive control for MUC5AC expression, 19 and salivary tissue was a positive control for MUC5B expression. 20 
QUANTITATIVE ANALYSES OF SUBMUCOSAL GLANDS
Three randomly selected fields of AB/PAS-stained tissues in each specimen were analyzed. Under ϫ200magnification, fields were ARCH OTOLARYNGOL HEAD NECK SURG/ VOL 137 (NO. 4), APR 2011 WWW.ARCHOTO.COM 384 captured from each section with a charger-coupled device camera-assisted microscope (Nikon Eclipse E800; Nikon, Tokyo, Japan) and the images were analyzed (Image J; http://rsb.info .nih.gov/ij). The ratio between the area of AB/PAS-stained glands and total area of tissue was recorded. Data were presented as the mean of 3 fields for each specimen.
A grading classification of MUC5B staining in SMGs was developed to account for variable MUC5B staining in each specimen and allow comparison between the 2 groups under investigation. Grade 1 was considered an area of MUC5B-positive staining that was 50% or less of the total SMG area per highpower field (ϫ400); grade 2, an area of MUC5B-positive staining that was more than 50% but less than 100% of the total SMG area; and grade 3, 100% of the glandular area was positive for MUC5B staining. Two observers (M.M.A. and M.T.P.) masked to the patients' clinical profile and type of mucosal sample independently evaluated the slides.
QUANTIFICATION OF EPITHELIAL CELLS
Specimens were coded and the number of AB/PAS-positive GCs and MUC5AC-or MUC5B-immunoreactive cells in the epithelial layer of the sinus mucosa in 10 high-power field was counted by 2 observers (M.M.A. and M.T.P.) (Olympus light microscope BH2; Olympus, Tokyo). A 1-cm 2 grid reticle divided into 100 square units was used to quantify cell number per millimeter of epithelium. The length of each unit was measured to be 0.25 mm of tissue at a magnification of ϫ400.
21 Cells in 4 of these units (0.25 mm each) were counted to determine the number of GCs and MUC5AC/MUC5B staining cells per millimeter of tissue. Only sections with distinct, intact, positively staining cells containing nuclei were counted.
STATISTICAL ANALYSES
To quantitatively evaluate differences in SMGs in CRS/CF and disease control specimens, data were analyzed by a nonpaired 2-sample t test, assuming nonequal variances. The closeness of the independent counts by 2 observers for the numbers of epithelial cells, mucin-positive cells in the epithelium, and glandular MUC5B-positive cells was analyzed to determine their intraclass coefficient correlation by a Pearson correlation program (SPSS Inc, Chicago, Illinois). Statistical analyses were performed using commercial software (SPSS and Microsoft Excel 2003; Microsoft Corporation, Redmond, Washington).
MUCIN LOCALIZATION BY MULTICHANNEL FLUORESCENCE MICROSCOPY
Deparaffinized and rehydrated slides were placed in 10mM sodium citrate buffer (pH, 6.0) and boiled for 10 minutes at 95°C for antigen unmasking. For dual staining, tissues were incubated with mouse anti-MUC5AC primary monoclonal antibody (1:200; Lab Vision Corporation) and rabbit anti-MUC5B primary polyclonal antibody (1:100, sc-20119; Santa Cruz Biotechnology, Inc) overnight at 4°C and then with the secondary fluorescent-labeled antibodies Alexa Fluor 488 goat antimouse IgG (1:250, A11004; Invitrogen, Carlsbad, California) and Alexa Fluor 568 goat antirabbit IgG (1:250, A11004; Invitrogen) for 1 hour at room temperature. Sections were mounted (ProLong Gold antifade reagent, P36934; Invitrogen) with a cover glass and examined using a microscope (Zeiss LSM 510 confocal microscope; Carl Zeiss Microimaging, Thornwood, New York). For negative controls, the primary or secondary antibody was omitted. Images were taken at magnifications of ϫ200 and ϫ630 under oil immersion.
RESULTS
Sinus mucosa samples from 21 patients with CRS/CF
(age, 66-252 months; mean, 241 months) and 18 disease controls (age, 120-238 months; mean, 191 months) were studied.
HISTOCHEMICAL ANALYSES OF SINUS MUCOSA
The surface epithelial and submucosal microanatomical compartments from 8 CRS/CF and 8 disease control sinus mucosal specimens were evaluated histologically. Goblet cells and mucous cells in SMGs were identified by AB/PAS staining. 22 Staining was evaluated in the intact epithelium and glands (when present) of both cohorts. Figure 1 shows typical AB/PAS-positive cells in the surface epithelium of sinus mucosa from disease control ( Figure 1A ) and CRS/CF ( Figure 1D ) samples, demonstrating the presence of GCs in both cohorts. Submucosal glands were typically sparse in the sinus mucosa of disease control specimens but could be identified ( Figure 1B) ; they were abundant in CRS/CF sinus mucosa ( Figure 1E ).
COMPARISON OF SMG AREA IN DISEASE CONTROL AND CRS/CF SINUS MUCOSA
Differences in the area of SMGs in the CRS/CF and disease control populations were determined by image analysis for 15 specimens (6 disease control samples that contained SMGs and 9 with CRS/CF). The data demonstrated that the area of the glands was significantly increased 4.4-fold in samples from patients with CRS/CF compared with those from disease controls (Figure 2) (P=.02).
LOCALIZATION OF MUCIN EXPRESSION IN THE SINUS MUCOSA
Sinus mucosal samples from 8 of 21 patients with CRS/CF and 8 of 18 disease controls were used for immunohistochemical analysis of both MUC5AC and MUC5B. MUC5AC mucin was not expressed in SMGs of disease control samples where glands were identified ( Figure 1B) . Similar patterns were observed with mucosal specimens from patients with CRS/CF (data not shown). MUC5B expression, which was clearly detected in all SMGs in CRS/CF samples ( Figure 1E ) and in disease control samples (data not shown), was evaluated by a grading classification. Of 8 CRS/CF specimens, 75.0% had grade 2 (n=4) or grade 3 (n=2) MUC5B expression and 2 were scored as grade 1. Normal tissues (n = 6) were distributed evenly among all 3 grades. However, not all glandular cells or all SMGs in either the CRS/CF or disease control population expressed MUC5B. In independent masked analysis, 2 observers (M.M.A. and M.T.P.) were in 100% agreement on grading assessments. The data suggested a trend toward increased expression of MUC5B in the SMGs of CRS/CF specimens compared with disease control specimens. formed to determine the cellular localization of MUC5AC mucin protein in sinus tissues. Representative micrographs of MUC5AC expression in sinus mucosal specimens from disease controls are shown (Figure 1 ). MUC5AC-positive cells were localized exclusively to the epithelial compartment of the sinus mucosa ( Figure 1A ) and were not detected in SMGs ( Figure 1B) . Similar patterns were observed with mucosal specimens from patients with CRS/CF (data not shown). To confirm that the MUC5AC-positive cells were GCs, tissues were immunostained with anti-MUC5AC antibody and subsequently stained with AB/PAS. MUC5AC expression was localized to GCs for both the disease control and CRS/CF groups, but not all GCs expressed MUC5AC mucin. To determine whether GCs in the sinus mucosa of patients with CRS/CF expressed MUC5B mucin, similar analyses were performed. MUC5B-positive cells were well expressed in a subset of GCs in the sinus mucosa in both the disease control (data not shown) and CRS/CF groups ( Figure 1D ).
QUANTIFICATION OF GCS AND MUC5AC/MUC5B-POSITIVE CELLS
To determine whether there was increased GC hyperplasia or increased MUC5AC or MUC5B expression in the epithelial layer of CRS/CF sinus mucosa, specimens from both cohorts were reviewed. Sinus mucosa from 8 disease controls were used for MUC5AC analyses, but only 5 of 8 CRS/CF specimens used for immunohistochemical analysis had sufficiently well-preserved epithelium for MUC5AC quantitative studies. Five samples from 4 patients with CRS/CF and 4 from 4 disease control patients were used for MUC5B analyses. The ratio of MUCpositive cells to AB/PAS-positive cells per millimeter of sinus mucosal epithelium is summarized in Table 1 and  Table 2 . There were no significant differences in the The ratio of SMG area to total tissue area was averaged for disease control (n = 6) and for chronic rhinosinusitis/cystic fibrosis (CRS/CF) specimens (n = 9) and shown as a bar graph. *A statistically significant increase of SMG area in CRS/CF sinus mucosa was observed (t test, P = .02).
Limit lines indicate SE.
number of GCs staining for either MUC5AC or MUC5B between the CRS/CF and disease control groups and no significant differences between the number of GCs in the disease control vs the CRS/CF cohorts. However, considerable variability with regard to GCs in CRS/CF specimens was noted. Denuded segments of epithelium were often seen in the CRS/CF samples, and there were regions in the epithelium layer of the mucosa where the majority of GCs expressed either MUC5AC or MUC5B.
There was a significant correlation between the cell counts by the 2 different analysts for MUC5AC expression (PϽ .001; Pearson correlation, 0.93), MUC5B expression (P=.04; Pearson correlation, 0.69), AB/PAS GCs stained in the MUC5AC group (P = .001; Pearson correlation, 0.78), and AB/PAS-positive cells between both groups (PϽ .001; Pearson correlation, 0.79). The only group that showed a weak correlation was the AB/PAS GCs counted in the MUC5B group in CRS/CF patients (Pearson correlation, 0.01).
COLOCALIZATION OF MUC5AC AND MUC5B MUCINS IN GOBLET CELLS
To determine whether MUC5AC and MUC5B mucins were expressed in the same GCs or in different subsets, double immunofluorescent staining and multichannel fluorescence microscopy were used on sinus tissues from 4 patients with CRS/CF and 4 disease controls. Colocalization studies demonstrated the presence of (1) a subset of GCs that expressed only MUC5AC ( Figure 3A) , ( 2) a subset of GCs that expressed only MUC5B ( Figure 3B ), and (3) a small subset of GCs in which MUC5AC and MUC5B mucins were colocalized ( Figure 3D ). There were no apparent differences in the colocalization and distribution of either MUC5AC or MUC5B in the sinus epithelium of the disease control and CRS/CF specimens.
COMMENT
Mucus overproduction/hypersecretion is related to the pathophysiologic characteristics of obstructive diseases in the upper (CRS, CRS/CF) and lower (CF) respiratory tracts. Cystic fibrosis is characterized by chronic inflammation and infection and overproduction of highly viscous mucus that obstructs the respiratory tracts. Mutations in CFTR are responsible for the clinical manifestations of CF, but it remains unclear how they translate into various phenotypic presentations. 1, 4 Recent studies 23 have suggested that other genes, including those involved in airway defense, ion transport, and lipid metabolism, may play a significant role in determining the clinical presentation of each patient with CF. Chronic rhinosinusitis, on the other hand, is characterized by poor ciliary function and edema, inflammation, and stagnant mucus in the sinus mucosa that may reflect dysfunctional host immune responses. 24 Chronic rhinosinusitis is often manifested in CF, with 20% of patients developing nasal polyposis and most becoming infected with bacterial pathogens in their upper respiratory tract. 4 Therapy for patients with CRS/CF is particularly challenging, both medically and surgically, because of their recalcitrant sinus disease and nasal polyposis. 2, 25 
